These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 17077178)
21. Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2). Langer I; Gaspard N; Robberecht P Br J Pharmacol; 2006 Aug; 148(8):1051-9. PubMed ID: 16783404 [TBL] [Abstract][Full Text] [Related]
22. Alterations of vasoactive intestinal polypeptide receptors in allergic rhinitis. Kim DH; Park IH; Cho JS; Lee YM; Choi H; Lee HM Am J Rhinol Allergy; 2011; 25(1):e44-7. PubMed ID: 21711977 [TBL] [Abstract][Full Text] [Related]
23. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles. Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411 [TBL] [Abstract][Full Text] [Related]
24. Activation of the VIP/VPAC2 system induces reactive astrocytosis associated with increased expression of glutamate transporters. Nishimoto M; Miyakawa H; Wada K; Furuta A Brain Res; 2011 Apr; 1383():43-53. PubMed ID: 21281617 [TBL] [Abstract][Full Text] [Related]
25. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries. Grant S; Lutz EM; McPhaden AR; Wadsworth RM J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462 [TBL] [Abstract][Full Text] [Related]
26. Ageing and the diurnal expression of mRNAs for vasoactive intestinal peptide and for the VPAC2 and PAC1 receptors in the suprachiasmatic nucleus of male rats. Kalló I; Kalamatianos T; Piggins HD; Coen CW J Neuroendocrinol; 2004 Sep; 16(9):758-66. PubMed ID: 15344914 [TBL] [Abstract][Full Text] [Related]
27. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. Voice JK; Grinninger C; Kong Y; Bangale Y; Paul S; Goetzl EJ J Immunol; 2003 Jan; 170(1):308-14. PubMed ID: 12496414 [TBL] [Abstract][Full Text] [Related]
28. Alterations in the relative abundance of the vasoactive intestinal peptide receptors (VPAC1 and VPAC2) and functions in uterine contractility during inflammation. Palus K; Całka J; Jana B Anim Reprod Sci; 2021 Feb; 225():106680. PubMed ID: 33388613 [TBL] [Abstract][Full Text] [Related]
29. Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide. Fabricius D; O'Dorisio MS; Blackwell S; Jahrsdörfer B J Immunol; 2006 Nov; 177(9):5920-7. PubMed ID: 17056516 [TBL] [Abstract][Full Text] [Related]
30. Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets. Vuckovic A; Rondelet B; Brion JP; Naeije R Pediatr Res; 2009 Oct; 66(4):395-9. PubMed ID: 19581838 [TBL] [Abstract][Full Text] [Related]
31. Low levels of vasoactive intestinal peptide are associated with Chagas disease cardiomyopathy. Corrêa MV; da Costa Rocha MO; de Sousa GR; do Carmo Pereira Nunes M; Gollob KJ; Dutra WO; da Silva Menezes CA Hum Immunol; 2013 Oct; 74(10):1375-81. PubMed ID: 23800435 [TBL] [Abstract][Full Text] [Related]
32. Differential Expression of PACAP/VIP Receptors in the Post-Mortem CNS White Matter of Multiple Sclerosis Donors. Jansen MI; Musumeci G; Castorina A Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201536 [TBL] [Abstract][Full Text] [Related]
33. Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis. Vomhof-DeKrey EE; Sandy AR; Failing JJ; Hermann RJ; Hoselton SA; Schuh JM; Weldon AJ; Payne KJ; Dorsam GP Peptides; 2011 Oct; 32(10):2058-66. PubMed ID: 21878358 [TBL] [Abstract][Full Text] [Related]
34. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Valdehita A; Bajo AM; Fernández-Martínez AB; Arenas MI; Vacas E; Valenzuela P; Ruíz-Villaespesa A; Prieto JC; Carmena MJ Peptides; 2010 Nov; 31(11):2035-45. PubMed ID: 20691743 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gonzalez-Rey E; Delgado M Gastroenterology; 2006 Dec; 131(6):1799-811. PubMed ID: 17087944 [TBL] [Abstract][Full Text] [Related]
36. Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells. Jimeno R; Leceta J; Martínez C; Gutiérrez-Cañas I; Carrión M; Pérez-García S; Garín M; Mellado M; Gomariz RP; Juarranz Y J Mol Neurosci; 2014 Nov; 54(3):512-25. PubMed ID: 24805298 [TBL] [Abstract][Full Text] [Related]
38. Role of vasoactive intestinal peptide in inflammation and autoimmunity. Gonzalez-Rey E; Delgado M Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132 [TBL] [Abstract][Full Text] [Related]
39. Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes. Lara-Marquez ML; O'Dorisio MS; Karacay B Ann N Y Acad Sci; 2000; 921():45-54. PubMed ID: 11193874 [TBL] [Abstract][Full Text] [Related]
40. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency. Langer I; Gregoire F; Nachtergael I; De Neef P; Vertongen P; Robberecht P Peptides; 2004 Feb; 25(2):275-8. PubMed ID: 15063009 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]